|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation显示文摘Background:Acute myeloid leukemia(AML) with t(8;21) is a heterogeneous disease.Identifying AML patients with t(8;21) who have a poor prognosis despite achieving remission is important for determining the best subsequent therapy.This study aimed to evaluate the impact of Wilm tumor gene-1(WT1) transcript levels and cellular homolog of the viral oncogene v-KIT receptor tyrosine kinase(C-KIT) mutations at diagnosis,and RUNXTRUNX1T1 transcript levels after the second consolidation chemotherapy cycle on outcomes.Methods:Eighty-eight AML patients with t(8;21) who received chemotherapy only or allogeneic hematopoietic stem cell transplantation(allo-HSCT) were included.Patients who achieved remission,received two or more cycles of consolidation chemotherapy,and had a positive measureable residual disease(MRD) test result(defined as <3-log reduction in RUNX1-RUNX1T1 transcript levels compared to baseline) after 2-8 cycles of consolidation chemotherapy were recommended to receive allo-HSCT.Patients who had a negative MRD test result were recommended to receive further chemotherapy up to only 8 cycles.WT1 transcript levels and C-KIT mutations at diagnosis,and RUNX1-RUNX1T1 transcript levels after the second consolidation chemotherapy cycle were tested.Results:Patients who had a C-KIT mutation had significantly lower WTl transcript levels than patients who did not have a C-KIT mutation(6.7%± 10.6%vs.19.5%± 19.9%,P < 0.001).Low WTl transcript levels(<5.0%) but not C-KIT mutation at diagnosis,a positive MRD test result after the second cycle of consolidation chemotherapy,and receiving only chemotherapy were independently associated with high cumulative incidence of relapse in all patients(hazard ratio[HR]= 3.53,2.30,and 11.49;95%confidence interval[CI]1.64-7.62,1.82-7.56,and 4.43-29.82;P = 0.002,0.034,and <0.001,respectively);these conditions were also independently associated with low leukemia-free survival(HR =3.71,2.33,and 5.85;95%CI 1.82-7.56,1.17-4.64,and 2.75-12.44;P < 0.001,0.016,and <0.001,respectively) and overall survival(HR = 3.50,2.32,and 4.34;95%CI 1.56-7.82,1.09-4.97,and 1.98-9.53;P = 0.002,0.030,and <0.001,respectively) in all patients.Conclusions:Testing for WTl transcript levels at diagnosis in patients with AML and t(8;21) may predict outcomes in those who achieve remission.A randomized study is warranted to determine whether allo-HSCT can improve prognosis in these patients. | Ya-Zhen Qin Yu Wang Hong-Hu Zhu Robert Peter Gale Mei-Jie Zhang Qian Jiang Hao Jiang Lan-Ping Xu Huan Chen Xiao-Hui Zhang Yan-Rong Liu Yue-Yun Lai Bin Jiang Kai-Yan Liu Xiao-Jun Huang | 2016 | Chinese Journal of Cancer2016，35，7： | 7 |
| 2 | A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR显示文摘 | Hillard M. Lazarus Mei-Jie Zhang Jeanette Carreras Brandon M. Hayes-Lattin Asli Selmin Ataergin Jacob D. Bitran Brian J. Bolwell César O. Freytes Robert Peter Gale Steven C. Goldstein Gregory A. Hale David J. Inwards Thomas R. Klumpp David I. Marks Richar | 2010 | Biology of Blood and Marrow Transplantation2010，，1： | 1 |
| 3 | Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report from The Center For International Blood & Marrow Transplant Research (CIBMTR)显示文摘 | Hillard M. Lazarus Jeanette Carreras Christian Boudreau Fausto R. Loberiza James O. Armitage Brian J. Bolwell César O. Freytes Robert Peter Gale John Gibson Gregory A. Hale David J. Inwards Charles F. LeMaistre Dipnarine Maharaj David I. Marks Alan M. Mil | 2008 | Biology of Blood and Marrow Transplantation2008，，12： | 1 |
| 4 | ABO Blood Group Barrier in Allogeneic Bone Marrow Transplantation Revisited显示文摘 | J?rg D. Seebach Georg Stussi Jakob R. Passweg Fausto R. Loberiza James L. Gajewski Armand Keating Martin Goerner Philip A. Rowlings Pierre Tiberghien Gerald J. Elfenbein Robert Peter Gale Jon J. van Rood Vijay Reddy Eliane Gluckman Brian J. Bolwell Thomas | 2005 | Biology of Blood and Marrow Transplantation2005，，12： | 1 |
| 5 | Will immune therapy cure acute myeloid leukemia?显示文摘The truth will set you free but first it will make you miserable.President James A.Garfield There is considerable recent progress in using immune therapy to treat diverse cancers.In hematology this progress is concentrated in therapy of lymphoid cancers including acute lymphoblastic leukemia(ALL),lymphomas,and plasma cell myeloma.Effective therapies include monoclonal antibodies such as rituximab,antibody-drug conjugates such as brentuximab vedotin,antibody-radionuclide conjugates such as 131-iodine tositumomab,bi-specific monoclonal antibodies(BiTE®antibodies)such as blinatumomab and chimeric antigen receptor T-cells(CAR-T-cells)to CD19,CD20,and to BCMA.The target of these immune therapies is B-cell lineage antigens such as CD19,CD20,and BCMA rather than cancer-specific antigens.Efficacy of these interventions is more effective than checkpoint-inhibition directed antibodies such as those to PD-1,or PD-1L or antibodies to CTLA-4 which are more effective in solid cancers. | Robert Peter Gale | 2019 | Blood Science2019，1，1： | 0 |
| 6 | Chimeric antigen receptor-T-cell therapy: China leading the way显示文摘Clinical trials of chimeric antigen receptor(CAR)-T-cell ther-apy in China far outnumber those in other countries including the United States.A recent Boolean search on ClinicalTrials.gov for CAR-T-cells AND leukaemia identified 188 studies compared 99 studies in the United States.In lymphoma,there are 234 studies in China versus 159 in the United States and in plasma cell myeloma,64 versus 55. | Robert Peter Gale | 2022 | Blood Science2022，4，3： | 0 |
| 7 | Chronic lymphocytic leukemia in China显示文摘Chronic lymphocytic leukemia(CLL)is 10-to 20-fold less common in Han Chinese in China compared with persons of predominately European descent translating to inci-dences of 0.2 to 0.6 per 10E+5 population/year vs.4.6 per 10E+5 population/year.[1-3] Reason(s)for this markedly lower incidence and therefore prevalence in China is unknown but is shared with the other Asian nationalities including.Japanese,Koreans,and others,.+-61 Studies of large cohorts of Chinese with CLL are relatively rare and there are no population-based studies in the mainland of China.Several seeming differences between CLL in Chinese and persons of predominately European descent are reported such as younger age at diagnosis,different background genotypes,increased frequency of IGHV mutation,different stereotype use and different mutation topographies.7 However,in general,most cases of CLL in Han Chinese are like CLL in persons of predominately European descent. | Robert Peter Gale | 2022 | Chinese Medical Journal2022，，8： | 0 |
| 8 | Measurable residual disease in childhood B-cell acute lymphoblastic leukemia显示文摘In a recent report in Nature Cell Biology(2022.24:242–52)Zhang and coworkers discuss comparative genetic and biochemical features of leukemia cells from children with B-cell acute lymphoblastic leukemia(ALL)obtained at diagnosis,in remission,and at relapse.1 The authors analyzed large numbers of single-cell transcriptomes looking for dynamic changes and simultaneously,B-cell receptor sequences.They report that in contrast to leukemia cells at diagnosis,those at relapse shifted to a poorly-differentiated state.Changes in residual leukemia cells in remission were more complicated. | Robert Peter Gale | 2022 | Blood Science2022，4，4： | 0 |
| 9 | Mesenchymal stromal cells and leukemia therapy in mice and man显示文摘Mesenchymal stromal cells(MSCs)and macrophages are normal components of the bone marrow micro-environment and important regulators of normal hematopoiesis.1 Consequently,MSC and macrophage dysfunctions are associated with an abnormal bone marrow micro-environment and abnormal hematopoiesis.In some circumstances,these abnormalities support the growth of leukemia cells but how this occurs is unknown.Also unknown is whether there is an important interaction between these cell types. | Robert Peter Gale | 2020 | Blood Science2020，2，3： | 0 |
| 10 | 急性白血病的骨髓移植治疗显示文摘国际骨髓移植登记处已分析了5000例以上的HLA相合的同胞间急性白血病骨髓移植的资料,此报告主要是1985年到1990年的资料。 | Robert Peter Gale 曹履先 | 1992 | 山西白血病1992，1，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员